1 Epstein AE, Olshansky B, Naccarelli GV, Kennedy JI, Murphy EJ, Goldschlager N. Practical management guide for clinicians who treat patients with amiodarone. Am J Med. 2016;129(5):468–75.
2 Lustman F, Monseu G. Amiodarone and neurological side-effects. Lancet. 1974;1(7857):568.
3 Kaeser HE. Amiodaron-Neuropathie. Schweiz Med Wschr. 1974;104(17):606–8.
4 Morady F, Sauve MJ, Malone P, Shen EN, Schwartz AB, Bhandari A, Keung E, Sung RJ, Scheinman MM. Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. Am J Cardiol. 1983;52:975–9.
5 Charness ME, Morady F, Scheinman MM. Frequent neurologic toxicity associated with amiodarone therapy. Neurology. 1984;34:669–71.
6 Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997;30(3):791–8.
7 Binz-Siegmann K. Amiodaron-induzierte Schilddrüsenprobleme: optimales Management. Praxis. 2018;107(1):25–9.
8 Orr CF, Ahlskog JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol. 2009;66(7):865–9.
9 Anderson NE, Lynch NM, O’Brian KP. Disabling neurological complications of amiodarone. Aust NZ J Med. 1985;15:300–4.
10 Eschle D, Jenni W. Tremor – es ist nicht immer Parkinson! PrimaryCare. 2009;9:106–7.
11 Wang AG, Cheng HC. Amiodarone-associated optic neuropathy: clinical review. Neuro-Ophthalmology. 2017;41(2):55–8.
12 Gürkov R, Manzari L, Blödow A, Wenzel A, Pavlovic D, Luis L. Amiodarone-associated bilateral vestibulopathy. Eur Arch Otorhinolaryngol. 2018;275:823–5.
13 Abarbanel JM, Osiman A, Frisher S, Herishanu Y. Peripheral neuropathy and cerebellar syndrome associated with amiodarone therapy. Isr J Med Sci. 1987;23:893–5.
14 Arnaud A, Neau JP, Rivasseau-Jonveaux T, Marechaud R, Gil R. Toxicité neurologique de l’amiodarone. À propos de cinq observations. Rev Med Interne. 1992;13:419–22.
15 Callaghan BC, Price RS, Feldman EL. Distal symmetric polyneuropathy. A review. JAMA. 2015;314(20):2172–81.
16 Eschle D, Jenni W. Polyneuropathien – kurz und bündig. Praxis. 2010;99:779–84.
17 Martina ISJ, van Koningsveld R, Schmitz PIM, van der Meché FGA, van Doorn PA, for the European Inflammatory Neuropathy Cause and Treatment (INCAT) group. Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. J Neurol Neurosurg Psychiatry. 1998;65:743–7.
18 Pestronk A, Florence J, Levine T, Al-Lozi MT, Lopate G, Miller T, Ramneantu I, Waheed W, Stambuk M. Sensory exam with a quantitative tuning fork. Rapid, sensitive and predictive of SNAP amplitude. Neurology. 2004;62:461–4.
19 Bergin PS, Bronstein AM, Murray NMF, Sancovic S, Zeppenfeld K. Body sway and vibration perception thresholds in normal aging and in patients with polyneuropathy. J Neurol Neurosurg Psychiatry. 1995;58:335–40.
20 Ziegler D, Keller J, Maier C, Pannek J. Diabetische Neuropathie. Diabetologie. 2017;12(S2):S101–S114.